-
May 09, 2026PK Data As A Pharmacodynamic Biomarker: Advancing Translational Drug Developm...Discover how pharmacokinetic (PK) data functions as a pharmacodynamic biomarker in modern drug development. Learn how Prisys Biotech supports translational PK/PD research throug... -
Apr 24, 2026Non-GLP Pharmacology Studies For Regulatory Submission: Data Integrity & Labo...Learn how non-GLP pharmacology studies can support regulatory submissions through ALCOA+ data integrity, controlled laboratory practices, and translational NHP models from Prisy... -
Apr 20, 2026Strategic Design Of Nonclinical Pharmacokinetic Studies: From ADME Profiling ...Learn how to design robust nonclinical pharmacokinetic studies, including ADME profiling, dose selection, and sampling strategies. Discover how Prisys Biotech supports translati... -
Apr 17, 2026NHP AV-Shunt Thrombosis Model For Drug Safety Evaluation | Prisys BiotechExplore how Prisys Biotech uses NHP AV-shunt thrombosis and bleeding models to evaluate efficacy and bleeding risk of novel antibody therapeutics targeting coagulation pathways. -
Apr 14, 2026What Is Nonlinear Pharmacokinetics? Mechanisms And Translational PK Evaluatio...Learn what nonlinear pharmacokinetics is, its mechanisms, and why it matters in drug development. Discover how Prisys Biotech evaluates nonlinear PK using NHP models, PK/PD anal... -
Apr 10, 2026Prisys Biotech Supports IND Approval Of UX-GIP001 By FDA And CDE | NHP CNS De...UX-GIP001, an iPSC-derived cell therapy by UniXell Biotechnology, receives IND approvals from FDA and CDE. Prisys Biotech supports CNS delivery using NHP models and MRI-guided C... -
Apr 02, 2026In Vivo Immune Cell Tracking & PET Tracer Development in NHP Models | Prisys ...Explore how Prisys Biotech enables in vivo immune cell tracking and PET tracer development using NHP models and clinical-grade imaging platforms to accelerate translational drug... -
Mar 31, 2026Dopamine Transporter PET Imaging in NHP Models | CNS Imaging | Prisys BiotechExplore high-precision CNS imaging using dopamine transporter PET and hybrid PET/MRI in non-human primate models. Prisys Biotech enables quantitative, translational neuroimaging... -
Mar 27, 2026PET/CT Biodistribution in NHP Models For CNS Drug Delivery | Prisys BiotechQuantitative in vivo biodistribution of CNS drug delivery systems using PET/CT imaging in NHP models. Supporting translational research and nose-to-brain delivery evaluation. -
Mar 23, 2026Large-Animal Radiolabeling And In Vivo Imaging Platform For Translational Dru...Explore how radiolabeling and clinical imaging in non-human primates enable accurate in vivo PK and biodistribution data, supporting translational drug development. -
Mar 18, 2026Why Drug Development Increasingly Relies On NHP Models: The Essential Role Of...why non-human primate (NHP) models, such as cynomolgus and rhesus macaques, are essential for modern drug development and translational medicine. It highlights the biological, g... -
Mar 17, 2026IPF Drug Development Challenges And Solutions | NHP Models With CT Imaging & PFTExplore how advanced NHP pulmonary fibrosis models, quantitative CT imaging, and pulmonary function testing improve translational success in IPF drug development.
